Find link

language:

Find link is a tool written by Edward Betts.

searching for Immunomedics 9 found (22 total)

Milatuzumab (502 words) [view diff] exact match in snippet view article find links to article

myeloma and chronic lymphocytic leukemia. Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA). CD74 is present on a variety of hematological

Yttrium (90Y) clivatuzumab tetraxetan (126 words) [view diff] exact match in snippet view article

radioisotope which destroys the tumour cells. The drug was developed by Immunomedics, Inc. In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic

Epratuzumab (377 words) [view diff] exact match in snippet view article find links to article

doi:10.1182/blood-2011-02-336990. PMC 3204728. PMID 21673350. "UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic

Fast track (FDA) (808 words) [view diff] exact match in snippet view article

Track, Breakthrough Therapy, Accelerated Approval, Priority Review. [1] "Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132)

List of drugs: Ls–Ly (224 words) [view diff] exact match in snippet view article find links to article

Lyfgenia Lygen lymecycline (INN) Lymphazurin (Tyco Healthcare) LymphoScan (Immunomedics, Inc.) LymphoStat-B (GlaxoSmithKline) lynestrenol (INN) Lynoral Lyophilized

Scripps Research (2,404 words) [view diff] exact match in snippet view article find links to article

Answers". USC News. Retrieved 2022-07-21. "2019 Annual Report" (PDF). Immunomedics. "U.S. News & World Report rankings for Scripps Research Institute".

Trogocytosis (2,135 words) [view diff] exact match in snippet view article find links to article

7435–7443. doi:10.4049/jimmunol.177.10.7435. PMID 17082663. "Epratuzumab". Immunomedics. Daubeuf, Sandrine; Puaux, Anne-Laure; Joly, Etienne; Hudrisier, Denis

Triple-negative breast cancer (3,411 words) [view diff] exact match in snippet view article find links to article

(Trodelvy) is an anti-Trop-2 antibody linked to SN-38, developed by Immunomedics Inc. (now Gilead Sciences). It was approved by the FDA on 22 April 2020

TACSTD2 (1,181 words) [view diff] exact match in snippet view article find links to article

Center for Biotechnology Information, U.S. National Library of Medicine. Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132)